Malaria

The R21/Matrix-M malaria vaccine has been recommended for use by the World Health Organization’s Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG). Developed by The University of Oxford and the Serum Institute of India, leveraging Novavax’s adjuvant technology, R21/Matrix-M malaria vaccine demonstrates high efficacy with a reassuring safety profile. It […]

Research published in Science shows that a naturally occurring bacterium discovered by GSK scientists – Delftia tsuruhatensis Tres Cantos 1 (TC1) – could be the basis for new anti-malarial interventions. Studies done in collaboration at the Johns Hopkins Malaria Research Institute show that the bacterium can significantly reduce the malaria parasite load in both the […]

News round-up for 10-14 April by DDW Digital Content Editor Diana Spencer. The headlines getting our attention this week all represent significant breakthroughs in the treatment of various diseases and could make a huge difference to the lives of these patients. Perhaps most significantly, Ghana accepted the R21/Matrix-M malaria vaccine for use in children, Moderna […]

The R21/Matrix-M malaria vaccine has received regulatory clearance for use in Ghana by the country’s Food and Drugs Authority, making it the first country to approve the vaccine. R21/Matrix-M was developed by the University of Oxford and manufactured and scaled up by the Serum Institute of India (SIIPL), leveraging Novavax’s adjuvant technology. The vaccine has […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  The industry has seen breakthroughs announced in malaria treatment, epilepsy and major depressive disorders. The NHS in England has fast tracked another […]

News round-up for 28 November – 2 December by DDW Digital Content Editor Diana Spencer  The last seven days have seen breakthroughs announced in malaria treatment, epilepsy and major depressive disorders. The NHS in England has fast tracked another cancer drug, and, in Covid-19 news, researchers have emphatically proven that prednisolone should not be prescribed […]

Novartis and Medicines for Malaria Venture (MMV) will progress ganaplacide/lumefantrine-solid dispersion formulation (SDF) into Phase III development for the treatment of patients with malaria due to Plasmodium falciparum.    Ganaplacide is a novel agent with a new mechanism of action, which is combined with a new formulation of lumefantrine optimised for once-daily dosing.   The combination has […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In a week that saw magic mushrooms making the headlines in the UK, we also reported on exciting potential new […]

News round-up for 31 October – 4 November by DDW Digital Content Editor Diana Spencer  In a week that saw magic mushrooms making the headlines in the UK, we also reported on exciting potential new therapies for geographic atrophy and malaria prevention. Meanwhile, the quest to understand Covid-19 continues, as study findings reveal how the […]

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa.   The antibody was up to 88.2% effective at preventing infection over a 24-week period, demonstrating for the first time that a monoclonal antibody can prevent malaria infection in an endemic region.  The […]

This week in drug discovery (26-30 September) News round-up by DDW Editor Reece Armstrong. An interesting week across the board for the pharma sector with the first biologic for severe asthma approved in the EU. Elsewhere researchers have discovered new ways of  identifying cancer cells and a manufacturing system could advance the development and production […]

US biotechnology start-up LivFul has secured a $1.5m investment to expand its work saving lives from malaria and other insect-borne diseases, and to support the company’s growth plans.    The company’s major markets are now opening up following the pandemic, with interest in Livful’s Enhanced Insect Repellent ramping up. Livful is currently focussing its business development […]

A monoclonal antibody (mAb) treatment for the prevention of Malaria has shown encouraging results in a US Phase I clinical trial.   The mAb, known as L9LS, was developed by scientists at the National Institutes of Health’s (NIH) Vaccine Research Centre (VRC). L9LS is a laboratory-made version of a naturally occurring antibody called L9, developed from […]

News round-up by DDW’s Reece Armstrong for 25-29 April     Q1 earnings, formulations to tackle blindness, liver cancer therapies and opportunities for malaria treatments are some of the themes of this week’s news round-up.  What’s behind GSK’s strong Q1 earnings?  DDW Deputy Editor Reece Armstrong looks at the key points of GSK’s first quarter earnings. UK […]

Despite continuous work by the scientific community, malaria remains one of the largest and deadliest diseases on the planet. The disease, which is spread via the bites of female Anopheles mosquitoes, was responsible for 627,000 deaths in 2020, with 95% of those occurring in Africa.    The disease largely affects at-risk groups such as infants, children […]

As we celebrate World Health Day, Lu Rahman looks at some of the key drug discovery and development successes over the last year that have significantly helped improved the health and wellbeing of the global population.   Malaria breakthroughs  According to The World Health Organization (WHO) more than a million people in Africa die from malaria every year, including 3,000 children […]